- Home
- ZNTL vs FHTX Comparison
ZNTL vs FHTX Comparison
Compare ZNTL & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- FHTX
- Stock Information
- Founded
- ZNTL 2014
- FHTX 2015
- Country
- ZNTL United States
- FHTX United States
- Employees
- ZNTL N/A
- FHTX N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- ZNTL Health Care
- FHTX Health Care
- Exchange
- ZNTL Nasdaq
- FHTX Nasdaq
- Market Cap
- ZNTL 105.8M
- FHTX 271.5M
- IPO Year
- ZNTL 2020
- FHTX 2020
- Fundamental
- Price
- ZNTL $1.33
- FHTX $5.40
- Analyst Decision
- ZNTL Buy
- FHTX Strong Buy
- Analyst Count
- ZNTL 7
- FHTX 8
- Target Price
- ZNTL $8.60
- FHTX $12.63
- AVG Volume (30 Days)
- ZNTL 1.4M
- FHTX 146.4K
- Earning Date
- ZNTL 08-08-2025
- FHTX 08-07-2025
- Dividend Yield
- ZNTL N/A
- FHTX N/A
- EPS Growth
- ZNTL N/A
- FHTX N/A
- EPS
- ZNTL N/A
- FHTX N/A
- Revenue
- ZNTL $26,865,000.00
- FHTX $23,504,000.00
- Revenue This Year
- ZNTL N/A
- FHTX $33.60
- Revenue Next Year
- ZNTL N/A
- FHTX $5.87
- P/E Ratio
- ZNTL N/A
- FHTX N/A
- Revenue Growth
- ZNTL N/A
- FHTX N/A
- 52 Week Low
- ZNTL $1.01
- FHTX $2.95
- 52 Week High
- ZNTL $5.44
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- ZNTL 50.91
- FHTX 64.55
- Support Level
- ZNTL $1.15
- FHTX $4.78
- Resistance Level
- ZNTL $1.38
- FHTX $5.52
- Average True Range (ATR)
- ZNTL 0.10
- FHTX 0.32
- MACD
- ZNTL 0.01
- FHTX 0.05
- Stochastic Oscillator
- ZNTL 75.00
- FHTX 86.67
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.